About FLU-v – a Phase III enabled, broad spectrum stand-alone, universal influenza vaccine candidate
FLU-v, is a novel first-in-class, broad spectrum, true stand-alone, influenza vaccine candidate. FLU-v is designed to provide broad spectrum cover against multiple influenza strains and does not require annual immunisation alongside an annual influenza vaccine to confer immunity. It is also designed to minimise the impact of the influenza virus by reducing symptoms, potentially relegating influenza to a much milder disease by stimulating an immune response mediated through T-cells and B-cells to the internal proteins, in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external proteins. In 2017, there were two FLU-v Phase IIb studies conducted– 003 (field study) and 004 (human viral challenge study).
FLU-v is being developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. In April 2016, hVIVO entered in a joint venture investment Imutex Limited with the SEEK Group to develop vaccines against influenza (FLU-V) and universal mosquito-borne diseases (AGS-v).
Imutex strengthened hVIVO’s commercial flu portfolio (FLU-v) and expanded it into the adjacent therapeutic area of mosquito-borne diseases
About SEEK Group (PepTCell Limited, trading as SEEK Group)
SEEK’s strategy is to bring safe, effective and low cost medicines to patients as quickly as possible, to radically improve human health in major disease areas.
It does this by:
Modifying existing medicines to improve their efficacy
Using existing medicines in new indications
Creating new chemical entities
Working in these different ways allows SEEK to optimise the regulatory approval pathway to ensure that we bring safe and effective products to patients in the shortest possible time.